The Rome Study demonstrated the value of extensive sequencing and discussion of individual cancer cases to offer tailored therapeutic choices.
BARCELONA, Spain — A trial conducted across 40 Italian centers has underscored the significance of a new mutational approach to cancer research. The Rome Study, presented at the, demonstrated the value of integrating comprehensive genomic profiling with case discussions by a panel of experts involved in molecular tumor boards . This approach has enabled the selection of the most suitable therapies to improve patient outcomes.
"Following discussions with the MTBs, patients with at least one target alteration were randomized in a 1:1 ratio to TT chosen by the board or to SoC chosen by the researcher," Botticelli explained.The study achieved its primary endpoint of objective response rate, with 17% in the TT group and 9.5% in the SoC group. Progression-free survival was also better in the TT group than in the SoC group, with median values of 3.7 months vs 2.8 months.
"We must undoubtedly look at agnostic treatments, based on the presence of a specific mutation, but without forgetting histology and other factors," added Federica Di Nicolantonio, MD, PhD, professor of oncology at the University of Turin, Turin, and oncologist at the Candiolo Cancer Institute, Candiolo, Italy, referring to the ESMO Tumour-Agnostic Classifier and Screener, a tool for assessing the agnostic potential of molecularly guided therapies and for steering drug development.
Genomic Medicine Biologic Therapy Biologics Targeted Therapy Targeted Cancer Therapy Cancer Malignant Neoplasia Carcinoma Malignant Neoplasm Italy Italian Tumor Healthcare And Medical Technology Health And Medical Tech Health And Med Tech Health And Medical Technology Healthcare Technology Medical Technology Board Certification Boards Board Recertification Histology
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Kidney models-on-a-chip taking a step toward personalized medicineA team developed a human iPS cell-derived kidney organoid-based proximal tubule-on-chip -- OPTECs-on-Chip -- that mimics in vivo renal physiology more closely than ever before. This model exhibits enhanced expression and polarity of essential renal transporters, making it a powerful tool for assessing drug transport and nephrotoxicity.
Read more »
Angels shortstop Zach Neto looks to take another step forward after encouraging seasonNeto, 23, has already shown himself to be an above-average major league shortstop in his first full season, but he and Manager Ron Washington both believe he can be even better.
Read more »
Green Groups Praise 'Step Forward' on Biden Old-Growth Forest PlanJessica Corbett is a senior editor and staff writer for Common Dreams.
Read more »
Seattle Seahawks Take 'Step Forward' After Win vs. Miami DolphinsThe Seattle Seahawks are still undefeated after beating the Miami Dolphins.
Read more »
Red Sox Shortstop's Improbable Comeback Bid Takes Another Big Step ForwardBoston Red Sox shortstop Trevor Story is set to begin a rehab assignment on Sunday.
Read more »
Tennessee Titans Defense Expected to Take Step ForwardThe Tennessee Titans had a mediocre defense last season, but that is no longer expected to be the case.
Read more »